Abstract 192P
Background
Experimental and clinical studies have shown an increase in the level of interleukin-6 (IL-6) in the blood plasma and other cytokines in obstructive jaundice. The combination of a persistent increase in cytokines and an extended acute response phase is associated with a decrease in protein calories, leading to surgical complications and death.
Methods
The study involved 41 patients treated at the Gastroenterology department in 1st Republic Clinic, Tashkent aged from 33 to 84 years old (62.8 ± 2.14) were studied, of whom 26 (63.4%) were men and 15 (36.6%) were women. The duration of the icteric period by the time of admission to the hospital averaged 28.7 ± 2.18 days. At the same time, in 6 (14.6%) patients the duration of cholestasis was up to 15 days, in 10 (24.4%) - from 15 to 30 days, in 25 (61.0%) - more than 1 month. Percutaneous transhepatic cholangiography (PTCH) with per-cutaneous transhepatic cholangiostomy (PTCHS) was performed for all patients, regardless of the localization of the tumor process. The level of IL-6 in serum and bile was determined by ELISA method.
Results
The concentration of IL-6 before the overlap of PTCH in the serum was higher than normal, averaging 152.65 ± 16.3 pg/ml. Immediately after the overlaying of PTCH in bile, this indicator was on average 68.58 ± 7.24 pg/ml. The high content of IL-6 in serum and bile testified to a pronounced endogenous intoxication of the body. The concentration of IL-6 in the initial day after the imposition of PTCH in serum decreased to 32.9%. In the following days, this indicator remained virtually unchanged, but on the 6th day of observation, there was a slight increase in his blood. In the bile at the same time, the concentration of IL-6 decreased by 17.1%. These indicators remained virtually unchanged up to 6 days of observation. On the 14th day, the decrease in the level of IL-6 in the blood compared to baseline was 64.4%, and in the bile 54.3% (P < 0.001).
Conclusions
Thus, the determination of IL-6 in the blood and in the bile makes it possible to more objectively evaluate the tumor process and the cytokine-induced endogenous intoxication to the response of the therapeutic measures taken in biliopancreatoduodenal tumors complicated by the mechanical jaundice.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
259P - The BOT patients fail to benefit from surgical staging procedures in prognosis and fertility outcomes: A retrospective analysis
Presenter: Li Na
Session: Poster display session
Resources:
Abstract
260P - Malignant ovarian germ cell tumours (MOGCT): Treatment results of 149 pts
Presenter: Dzhennet Chekini
Session: Poster display session
Resources:
Abstract
261P - Ovarian germ cell tumours - challenges and outcomes from a tertiary care centre in South India
Presenter: Vishnu Sreedath
Session: Poster display session
Resources:
Abstract
262P - Gestational trophoblastic tumours: Experience of the medical oncology department Hassan II University Hospital-Morocco about 29 cases
Presenter: Karima Oualla
Session: Poster display session
Resources:
Abstract
263TiP - ATHENA (GOG-3020/ENGOT-ov45): A randomised, double-blind, placebo-controlled phase III study of the poly (ADP-ribose) polymerase (PARP) inhibitor rucaparib + the PD-1 inhibitor nivolumab following frontline platinum-based chemotherapy in ovarian cancer
Presenter: Keiichi Fujiwara
Session: Poster display session
Resources:
Abstract
264TiP - ENGOT-ov43/KEYLYNK-001: A phase III trial of pembrolizumab plus chemotherapy with olaparib maintenance for first-line treatment of BRCA¬-nonmutated advanced epithelial ovarian cancer
Presenter: Keiichi Fujiwara
Session: Poster display session
Resources:
Abstract
265TiP - KEYNOTE-826: A phase III randomized study of chemotherapy with or without pembrolizumab for first-line treatment of persistent, recurrent, or metastatic cervical cancer
Presenter: Keiichi Fujiwara
Session: Poster display session
Resources:
Abstract
271P - Comparison between CHOP like regimens and DAEPOCH with or without Rituximab in adult high grade B cell lymphoma NOS; A retrospective study from a tertiary cancer hospital in South India
Presenter: LALATENDU MOHARANA
Session: Poster display session
Resources:
Abstract
272P - Melatonin increases the chemosensitivity of diffuse large Bell lymphoma cells to Epirubicin by inhibiting P-glycoprotein expression via the NF-κB pathway
Presenter: Xiuhua Sun
Session: Poster display session
Resources:
Abstract
273P - MALT1- A20 and NF-κB expression pattern in patients with non-Hodgkin lymphomas
Presenter: Alshimaa Alhanafy
Session: Poster display session
Resources:
Abstract